Avalo Therapeutics, Inc.AVTXNASDAQ
Loading
Cost of Revenue Over TimeContracting
Percentile Rank23
3Y CAGR-83.3%
5Y CAGR-44.4%
Year-over-Year Change
Direct costs attributable to producing goods sold
3Y CAGR
-83.3%/yr
vs -17.7%/yr prior
5Y CAGR
-44.4%/yr
Recent deceleration
Acceleration
-65.6pp
Decelerating
Percentile
P23
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 yr
Consecutive growthContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $16000.00 | +104.4% |
| 2024 | $-366000.00 | -128.5% |
| 2023 | $1.28M | -62.6% |
| 2022 | $3.43M | +130.3% |
| 2021 | $1.49M | +397.0% |
| 2020 | $300000.00 | +153.0% |
| 2019 | $-566523.00 | -107.6% |
| 2018 | $7.48M | +1076.5% |
| 2017 | $635648.00 | -92.3% |
| 2016 | $8.24M | - |